Systematic review: Representativeness of participants in RCTs of acetylcholinesterase inhibitors

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Leinonen, Anne ^a   Koponen, Marjaana ^a   Hartikainen, Sirpa ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; PSYCHOTROPIC AGENT; RIVASTIGMINE;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; COMORBIDITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX RATIO; SYSTEMATIC REVIEW; TREATMENT DURATION; AGE; META ANALYSIS; PATHOLOGY; VERY ELDERLY;

SCOPUS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COMORBIDITY; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84929192411     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124500     Document Type: Review

References (63)

1. European Commission. The 2012 ageing report: Economic and budgetary projections for the 27 EU member states (2010-2060). 01 Feb 2013. Available: http://ec.europa.eu/economy-finance/publications/european-economy/2012/pdf/ee-2012-2-en.pdf. Accessed 16 January 2014.
2. Cerreta F, Eichler H, Rasi G. Drug policy for an aging population-the european medicines agency's geriatric medicines strategy. N Engl J Med. 2012; 367: 1972-1974. doi: 10.1056/NEJMp1209034 PMID: 23171092
3. Rochon PA, Fortin PR, Dear KB, Minaker KL, Chalmers TC. Reporting of age data in clinical trials of arthritis. Deficiencies and solutions. Arch Intern Med. 1993; 153: 243-248. PMID: 8422212
4. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 2061-2067. PMID: 10615079
5. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003; 21: 1383-1389. PMID: 12663731
6. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001; 286: 708-713. PMID: 11495621
7. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002; 162: 1682-1688. PMID: 12153370
8. Giron MS, Fastbom J, Winblad B. Clinical trials of potential antidepressants: To what extent are the elderly represented: A review. Int J Geriatr Psychiatry. 2005; 20: 201-217. PMID: 15717338
9. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005; 23: 3112-3124. PMID: 15860871
10. Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J. 2003; 146: 250-257. PMID: 12891192
11. EFGCP Geriatric Medicines Working Party. EFGCP guidelines on medical research for and with older people in Europe. 27 May 2013. Available: https://www.kcl.ac.uk/sspp/departments/sshm/news/EFGCP-GMWP-Research-Guidelines-Final-edited-2013-05-27.pdf. Accessed 21 February 2014.
12. Cherubini A, Del Signore S, Ouslander J, Semla T, Michel JP. Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010; 58: 1791-1796. doi: 10.1111/j.1532-5415.2010.03032.x PMID: 20863340
13. International conference on harmonization (ICH) expert working group. ICH harmonized tripartite guideline. Studies in support of special populations: geriatrics E7. 24 Jun 1993. Available: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E7/Step4/E7-Guideline.pdf. Accessed 07 March 2014.
14. European Medicines Agency. EMA geriatric medicines strategy. 17 Feb 2011. Available: http://www.ema.europa.eu/docs/en-GB/document-library/Other/2011/02/WC500102291.pdf. Accessed 23 January 2014.
15. Alzheimer's Disease International. World Alzheimer Report 2009. 2009. Available: http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf. Accessed 18 December 2013.
16. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. 2009 PLoS Med 6: e1000097. doi: 10.1371/journal.pmed.1000097 PMID: 19621072
17. Folstein MF, Folstein SE, McHugh PR. 'Mini mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198. PMID: 1202204
18. Tolppanen AM, Taipale H, Koponen M, Lavikainen P, Tanskanen A, Tiihonen J, et al. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research - the medication use among persons with Alzheimer's disease (MEDALZ-2005) study. Clin Epidemiol. 2013; 5: 277-285. doi: 10.2147/CLEP.S46622 PMID: 23950660
19. Suhonen J, Pirttila T, Erkinjuntti T, Koponen H, Makkonen M, Puurunen M, et al. Update on current care guidelines. The diagnosis and medical treatment of memory disorders. Duodecim 2010; 126: 2167-2168. PMID: 21072963
20. Working group set up by the Finnish Medical Society Duodecim, Societas Gerontologica Fennica, the Finnish Neurological Society, Finnish Psychogeriatric Association and the Finnish Association for General Practice. Memory disorders. Current care guideline. Helsinki: Finnish Medical Society Duodecim. 13 Aug 2010. Available: http://www.kaypahoito.fi. Accessed 05 January 2014.
21. McKhann G, Drachman D, Folstein M. Clinical diagnosis of alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 1984; 34: 939-944. PMID: 6610841
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington DC: American Psychiatric Association. 1994. 886 p.
23. Cohen AC. Estimating the mean and variance of normal populations from singly and doubly truncated samples. Ann Math Statist. 1950; 21: 557-569.
24. Rogers S, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996; 7: 293-303. PMID: 8915035
25. Sramek JJ, Anand R, Wardle TS, Irwin P, Hartman RD, Cutler NR. Safety/tolerability trial of SDZ ENA 713 in patients with probable alzheimer's disease. Life Sci. 1996; 58: 1201-1207. PMID: 8614273
26. Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research - Clinical and Experimental. 1998; 59: 837-845.
27. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998; 1: 55-65.
28. Rogers SL, Doody RS, Mohs RC, Friedhoff LT; the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998; 158: 1021-1031. PMID: 9588436
29. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998; 50: 136-145. PMID: 9443470
30. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord. 1999; 10: 237-244. PMID: 10325453
31. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol. 1999; 6: 423-429. PMID: 10362894
32. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. Br Med J. 1999; 318: 633-640.
33. Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, et al. Donepezil therapy in clinical practice: A randomized crossover study. Arch Neurol. 2000; 57: 94-99. PMID: 10634454
34. Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. Dement Geriatr Cogn Disord. 2000; 11: 299-313. PMID: 11044775
35. Raskind MA, Peskind ER, Wessel T, Yuan W, Allen FH, Aronson SM, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000; 54: 2261-2268. PMID: 10881250
36. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000; 54: 2269-2276. PMID: 10881251
37. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ. 2000; 321: 1445-1449. PMID: 11110737
38. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001; 57: 613-620. PMID: 11524468
39. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001; 57: 481-488. PMID: 11502917
40. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001; 71: 589-595. PMID: 11606667
41. Wilkinson D, Murray J. Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2001; 16: 852-857. PMID: 11571763
42. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001; 57: 489-495. PMID: 11502918
43. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry. 2003; 160: 2003-2011. PMID: 14594748
44. Lopez-Pousa S, Vilalta-Franch J, Hernandez B, Rapatz G. Efficacy of rivastigmine in patients with severe Alzheimer's disease: A double-blind, randomized pilot study. Brain Aging. 2004; 4: 26-34.
45. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial. Arch Neurol. 2004; 61: 1852-1856. PMID: 15596605
46. Brodaty H, Corey-Bloom J, Potocnik FCV, Truyen L, Gold M, Damaraju CRV. Galantamine prolongedrelease formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005; 20: 120-132. PMID: 15990426
47. Karaman Y, Erdogan F, Koseoglu E, Turan T, Ersoy AO. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005; 19: 51-56. PMID: 15383747
48. Rockwood K, Fay S, Song X, MacKnight C, Gorman M; the Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: A randomized controlled trial. CMAJ. 2006; 174: 1099-1105. PMID: 16554498
49. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007; 69: 459-469. PMID: 17664405
50. Feldman HH, Lane R. Rivastigmine: A placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007; 78: 1056-1063. PMID: 17353259
51. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month doubleblind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007; 22: 456-467. PMID: 17380489
52. Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord. 2008; 25: 399-407. doi: 10.1159/000122961 PMID: 18391486
53. Nakamura Y, Imai Y, Shigeta M, Graf A, Shirahase T, Kim H, et al. A 24-week, randomized, doubleblind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra. 2011; 1: 163-179. doi: 10.1159/000328929 PMID: 22163242
54. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Neuropsychiatr Dis Treat. 2014; 10: 391-401. doi: 10.2147/NDT.S57909 PMID: 24591834
55. Schoenmaker N, Van Gool WA. The age gap between patients in clinical studies and in the general population: A pitfall for dementia research. Lancet Neurol. 2004; 3: 627-630. PMID: 15380160
56. Gill SS, Bronskill SE, Mamdani M, Sykora K, Li P, Shulman KI, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol. 2004; 11: e274-85. PMID: 15604527
57. Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One. 2012; doi: 10.1371/journal.pone.0033559
58. Crome P, Lally F, Cherubini A, Oristrell J, Beswick AD, Clarfield AM, et al. Exclusion of older people from clinical trials: Professional views from nine European countries participating in the PREDICT study. Drugs Aging. 2011; 28: 667-677. doi: 10.2165/11591990-000000000-00000 PMID: 21812501
59. Alzheimer's Association. Research consent for cognitively impaired adults: Recommendations for institutional review boards and investigators. Alzheimer Dis Assoc Disord. 2004; 18: 171-175. PMID: 15494623
60. Dodd KS, Saczynski JS, Zhao Y, Goldberg RJ, Gurwitz JH. Exclusion of older adults and women from recent trials of acute coronary syndromes. J Am Geriatr Soc. 2011; 59: 506-511. doi: 10.1111/j.1532-5415.2010.03305.x PMID: 21361882
61. Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc. 1997; 45: 923-928. PMID: 9256842
62. Herrmann N, Gill SS, Bell CM, Anderson GM, Bronskill SE, Shulman KI, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc. 2007; 55: 1517-1523. PMID: 17697100
63. Anthony S, Pradier C, Chevrier R, Festraëts J, Tifratene K, Robert P, et al. The French National Alzheimer Database: A Fast Growing Database for Researchers and Clinicians. Dement Geriatr Cogn Disord. 2014; 38: 271-280. doi: 10.1159/000360281 PMID: 24994018